Hospital Mater Dei S.A (MATD3) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Hospital Mater Dei S.A stock BRL 6.76, price BRL 4.82, upside +40.2%, quality 66 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range R$3.20 – R$19.30 · fair‑value band R$3.30 – R$8.78 · the R$4.82 price screens below the R$6.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.
Follow Hospital Mater Dei in your weekly email
Every Wednesday you see whether Hospital Mater Dei is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hospital Mater Dei S.A. operates hospitals in Brazil. It engages in data and artificial intelligence business. The company was incorporated in 1973 and is headquartered in Belo Horizonte, Brazil. Hospital Mater Dei S.A. is a subsidiary of JSS Empreendimentos e Administração LTDA.
Stock analysis
Hospital Mater Dei S.A (MATD3) currently trades at R$4.82, while our model-based Fair Value estimate is R$6.76, implying the stock looks roughly 29% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of R$9.53 per share, and 14 of the 25 models we run sit above the R$4.82 price.
Bear case: the Asset-Based group reads lowest at R$1.49, and 11 of the 25 models stay below the price. Data coverage for this calculation is low.
Scenario range: R$3.30 (bear) to R$8.78 (bull), the price of R$4.82 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Hospital Mater Dei S.A reported revenue of R$2.2B in FY2025 versus R$1.0B in FY2021, a compound +20.7%/yr. Reported net income was R$111M in FY2025, compounding −6.6%/yr from FY2021.
Key figures
Market cap R$1.6B (≈ $289M) Micro · P/E ratio 8.6 · P/S ratio 0.69 · EPS (TTM) R$0.5600 · Dividend yield 3.1% · Net margin 6.1% · Return on equity 9.5% · Return on assets (EBIT) 4.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 40%, MATD3 screens cheaper than that median.
Fair Value models
BearR$3.30Fair Value R$6.76BullR$8.78
Price R$4.82 · Upside +40.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (R$0.3507 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.8%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.5%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in BRL ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in BRL: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+0.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.6%
Dividend (yield on the price)3.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 16%
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (Brazil: IMF forecast 3.3% a year to 2030, 5.4% from 2016 to 2025) that is about +9.6% a year for the price and +5.4% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside+40.2% · Above median
Profitability
Return on equity (12 months)9.5% · Above median
Return on assets2.6% · Below median
Net margin (12 months)6.1% · Above median
Operating margin (12 months)17.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)12.4% · Above median
Dividend yield (12 months)3.1% · Above median
Balance sheet
Debt / equity0.88× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)8.6× · Cheapest 25%
P/B1.09× · Cheaper than median
P/S (12 months)0.69× · Cheapest 25%
Price / free cash flow (fiscal year)9.8× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hospital Mater Dei S.A Fair Value". https://www.fairvalue-calculator.com/stock/MATD3
Frequently asked questions
Is Hospital Mater Dei S.A (MATD3) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of R$6.76 versus a price of R$4.82, about +40% upside (undervalued).
What is the fair value of MATD3?
Our model-based fair value for Hospital Mater Dei S.A is R$6.76 (as of Nov 9, 2026), built from audited fundamentals. The current price: R$4.82.
What is the quality score of MATD3?
Hospital Mater Dei S.A has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hospital Mater Dei S.A (MATD3)?
Our model-based price target is the fair value of R$6.76 (as of Nov 9, 2026) from 26 valuation models. Cautious scenario R$3.30, optimistic scenario R$8.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Hospital Mater Dei S.A stock forecast for 2026?
Our models put fair value at R$6.76, about +40% upside versus a price of R$4.82 (undervalued). Cautious scenario R$3.30, optimistic scenario R$8.78. The calculation is refreshed regularly with new filings.
What is the revenue of Hospital Mater Dei S.A (MATD3)?
Hospital Mater Dei S.A reported trailing-twelve-month revenue of about R$2.3B (latest available figure, as of Nov 9, 2026).
Does Hospital Mater Dei S.A pay a dividend?
Hospital Mater Dei S.A currently shows a dividend yield of 3.13% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Hospital Mater Dei S.A (MATD3) and when is the ex-dividend date?
Hospital Mater Dei S.A pays a dividend of R$0.151 per share a year, a dividend yield of 3.1%. The last ex-dividend date was Dec 9, 2025. The payout ratio is 27.0% of earnings. Free cash flow covers the dividend 3.28 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Hospital Mater Dei S.A (MATD3)?
For today's price to be fair in a discounted-cash-flow model, Hospital Mater Dei S.A would have to grow free cash flow by +13.2 % per year for five years (discount rate 14.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +24.8 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of MATD3 use?
Our models discount Hospital Mater Dei S.A at 14.2 %: a base by market capitalisation (micro), damped by beta 0.39, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hospital Mater Dei S.A that is +13.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (14.2 %) and the same formula as our fair value.
How much growth has Hospital Mater Dei S.A (MATD3) delivered so far?
Over the past 5 years revenue at Hospital Mater Dei S.A grew +24.8 % a year. The price currently implies free-cash-flow growth of +13.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hospital Mater Dei S.A (MATD3) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Hospital Mater Dei S.A (+13.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hospital Mater Dei S.A (MATD3)?
The free-cash-flow yield on the price is 10.24 %: that much free cash flow Hospital Mater Dei S.A produces per unit of market value. When it exceeds the discount rate of our models (14.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hospital Mater Dei S.A (MATD3)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hospital Mater Dei S.A it is R$6.76 per share (as of Nov 9, 2026), against a price of R$4.82. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Hospital Mater Dei S.A stock overvalued or undervalued in 2026?
As of Nov 9, 2026, MATD3 trades below its calculated fair value: price R$4.82, fair value R$6.76, a gap of about +40% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MATD3?
No. The price is what the market pays today (R$4.82); the fair value is what the company's own numbers justify (R$6.76). For Hospital Mater Dei S.A the two are R$1.94 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hospital Mater Dei S.A worth?
The market values Hospital Mater Dei S.A at about R$1.6B (market capitalisation, as of Nov 9, 2026). Per share that is R$4.82; our models calculate a fair value of R$6.76 per share.
What do the bullish and bearish scenarios say about MATD3?
Our models span a range for Hospital Mater Dei S.A: cautious scenario R$3.30, base R$6.76, optimistic R$8.78 per share (as of Nov 9, 2026, price R$4.82). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MATD3?
Hospital Mater Dei S.A trades at a price-to-earnings ratio of 8.6 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$6.76 is built from several models across several years. Other multiples: P/B 1.1, P/S 0.7, EV/EBITDA 4.8.
How solid is the balance sheet of Hospital Mater Dei S.A (MATD3)?
Balance-sheet figures for Hospital Mater Dei S.A (as of Nov 9, 2026): return on equity 9.5%, debt of 0.88 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is MATD3 from its 52-week high?
Hospital Mater Dei S.A trades at R$4.82, about 30% below its 52-week high of R$6.85 and 23% above the low of R$3.93 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of R$6.76 is for.
Which stocks are comparable to Hospital Mater Dei S.A?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hospital Mater Dei S.A stock attractive at the current price?
The data as of Nov 9, 2026: price R$4.82, calculated fair value R$6.76 (+40%), Quality Score 66/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MATD3 calculated?
We run Hospital Mater Dei S.A through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of R$6.76 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Hospital Mater Dei S.A currently trades 29% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hospital Mater Dei S.A (MATD3)?
The closing price on Nov 6, 2026 was R$4.82. Our model-based fair value is R$6.76, about +40% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hospital Mater Dei S.A right now?
The model range is unusually wide (R$3.30 to R$8.78). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Hospital Mater Dei S.A
How large is the market capitalisation of Hospital Mater Dei S.A (MATD3)?
The market capitalisation of Hospital Mater Dei S.A is R$1.6B (≈ $289M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hospital Mater Dei S.A (MATD3)?
The price-to-sales ratio of Hospital Mater Dei S.A is 0.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hospital Mater Dei S.A (MATD3)?
Earnings per share at Hospital Mater Dei S.A are R$0.5600 (price ÷ EPS = P/E 8.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hospital Mater Dei S.A (MATD3)?
The dividend yield of Hospital Mater Dei S.A is 3.1% (payout 27.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hospital Mater Dei S.A (MATD3)?
The net margin of Hospital Mater Dei S.A is 6.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hospital Mater Dei S.A (MATD3)?
The return on equity (ROE) of Hospital Mater Dei S.A is 9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hospital Mater Dei S.A (MATD3)?
On an EBIT basis the return on assets of Hospital Mater Dei S.A is 4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hospital Mater Dei S.A (MATD3)?
The operating margin of Hospital Mater Dei S.A is 17.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hospital Mater Dei S.A (MATD3)?
Revenue at Hospital Mater Dei S.A is growing +12.4% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hospital Mater Dei S.A (MATD3)?
Earnings per share at Hospital Mater Dei S.A are growing +71.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hospital Mater Dei S.A (MATD3) carry?
The net debt of Hospital Mater Dei S.A is R$803M (fiscal year 2025, ≈ 4.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hospital Mater Dei S.A in the live analysis
One click puts Hospital Mater Dei S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026